Clinical application of iopamidol (pamiray 300) for cerebral angiography

The aim of this study was to assess the clinical safety and efficacy of Pamiray 300 (Iopamidol; Dongkook Pharm, Seoul, Korea) as a nonionic contrast medium for cerebral angiography. One hundred patients undergoing cerebral angiography were randomly assigned to receive Pamiray 300 after written consent had been obtained. Patients with adverse reactions were divided into two groups. One group consisted of patients with minor adverse events such as heat sensation and pain, and the other group consisted of patients with major adverse events such as dyspnea, laryngeal edema and shock. The qualities of the radiographic images were stratified into five grades by three independent radiologists. No abnormality induced by Pamiray 300 was seen by a physical and neurological examination, blood pressure measurement, electrocardiogram, respiration rate measurement and partial fraction of arterial oxygen recording. No major and severe adverse events occurred throughout the study. Patient sex, age, disease category, underlying disease and administered contrast dosage showed no statistical significance with regards to the occurrence of adverse events. The opacification of blood vessels in all patients was 'good' or 'excellent'. Based on the results of this study, Pamiray 300 is a safe, efficacious and well-tolerated contrast medium for use in cerebral angiography. Thus, Pamiray 300 can be used as a competitive medium in cerebral angiography